MedTrace Logo

RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration

NCT03633084 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

RBM-007 Injectable Solution

(No additional description)

Sponsors & Collaborators

  • Ribomic USA Inc

    lead INDUSTRY

Principal Investigators

  • Yusuf Ali, Ph.D. · Ribomic USA Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-29
Primary Completion
2019-06-26
Completion
2019-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633084 on ClinicalTrials.gov